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Objectives To synthesise the prevalence of mental and substance use disorders in countries 
of the Eastern Mediterranean Region (EMR) of the World Health Organization. 
Methods The literature search was conducted across several databases in two phases.  First, 
we searched for systematic reviews and/or meta-analyses published before 2014, reporting 
prevalence estimates for mental disorders in the EMR. Then, we identified new primary cross-
sectional or longitudinal studies published between 2014 to 2020. Studies were included if 
they had a sample size of ≥ 450 and were conducted among the general adult population. 
Current, period and lifetime prevalence estimates for each disorder were pooled using 
random-effects meta-analyses, and subgroup analyses and meta-regressions were 
conducted. 
Findings Prevalence estimates were extracted from 54 cross-sectional studies across 15 
countries within the EMR. Pooled analyses of current, period and lifetime prevalence showed 
the highest prevalence for depression (14.8%, 95% confidence interval, CI: 10.7-20.1%), 
followed by generalised anxiety disorder (GAD) (10.4%, 95% CI: 7.1%-14.7%), post-traumatic 
stress disorder (7.2%, 95% CI: 2.9-16.6%), substance use (4.0%, 95% CI: 3.1-5.2%), 
obsessive compulsive disorder (2.8%, 95% CI: 1.6-4.9%), phobic disorders (1.8%, 95% CI: 
1.1-2.8%), panic disorders (1.1%, 95% CI: 0.6-2.2%), bipolar disorders (0.7%, 95% CI: 0.3–
1.6%) and psychosis (0.5%, 95% CI: 0.3-0.9%). Populations exposed to adverse events had 
higher prevalence of mental disorders than the general population. Period and lifetime 
prevalence showed little difference across mental disorders. More pronounced differences in 
prevalence were seen for depression and GAD, specifically between current and lifetime 
prevalence (depression: current prevalence 20.5% (95% CI: 14.9-27.4%), vs. lifetime 
prevalence: 4.2% (95%CI: 1.8-9.6%); GAD: current prevalence 10.3% (95% CI: 6.1-17.0), vs. 
lifetime prevalence: 4.5% (95% CI:2.4-8.3%). Differences between current and lifetime 
prevalence of mental disorders may be due to the use of different screening instruments and 
thresholds being applied.  
Conclusion The prevalence of mental and substance use disorders in the EMR is high. 
Despite substantial inter-survey heterogeneity, our estimates align with previous global and 
regional data on mental disorders. Our meta-review provides new evidence on the burden of 






Introduction   
 
Mental disorders contribute significantly to the global burden of disease, with common mental 
disorders (CMDs) such as depression, anxiety and post-traumatic stress disorders (PTSD) 
accounting for 41.9% of the burden (1). Globally, the 12-month prevalence of CMDs in adults 
is estimated to be 17.6% and the lifetime prevalence is 29.2% (2). Research suggests that  
prevalence of mental disorders is increasing in low-and-middle-income countries due to 
population growth and ageing (3).  An extensive body of research suggests that the experience 
of war, conflict, population displacement, infrastructure damage and unemployment leads to 
increased symptoms of depression, anxiety, trauma and stress-related disorders (4), and this 
is evident in countries located in the Eastern Mediterranean Region (EMR) of the World Health 
Organization (WHO) in which the 12-month prevalence of CMDs ranges between 11-40.1% 
(5) (list of EMR member countries included in Annex 1). Almost 85% of the EMR population 
have experienced a humanitarian crisis within the past two decades (6), with a higher 
prevalence of psychological distress seen in EMR populations experiencing significant conflict 
(5). 
Previous research investigated the prevalence of specific mental disorders in the EMR region 
(7,8) or within single EMR countries (9,10). For example, Travers et al. synthesized evidence 
on the prevalence of major depressive disorder within Africa and the Middle East (7), and 
Naveed et al. reported on the pooled prevalence of CMDs and substance use disorders in 
South Asia (8). Additionally, Sadeghirad and colleagues reviewed the prevalence of major 
depressive disorder in Iran (9), and Mirza and Jenkins assessed the evidence on the 
prevalence of anxiety and depressive disorders in Pakistan (10). However, there is a lack of 
recently synthesized information on the overall prevalence and determinants of priority mental 
disorders within the EMR.  
This systematic review and meta-analysis aims to provide updated pooled prevalence 
estimates of mental and substance use disorders within the EMR. The objectives of this review 
are to (a) aggregate prevalence estimates of mental and substance use disorders within the 
EMR (present pooled estimates of current, period and lifetime prevalence; and separate 
estimates for current, period and lifetime prevalence respectively); (b) estimate the prevalence 
among populations exposed to adversity (such as refugees or victims of natural disasters); 
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This review follows the Preferred Reporting Items for Systematic reviews and Meta-Analysis 
(PRISMA) guidelines (PRISMA checklist included in Annex 2) (11). The protocol was 
registered in the PROSPERO database in July 2020 with the registration number: 
CRD42020187388. 
Inclusion and exclusion criteria  
We included studies reporting current (such as 1- or 2-week, or 1 month), period (such as 6 
or 12 months) or lifetime prevalence estimates of the following mental disorders - depressive 
disorders, bipolar disorders, generalised anxiety disorder (GAD), panic disorder, obsessive-
compulsive disorder (OCD), social phobia, PTSD, acute stress disorder or any other anxiety 
disorder, psychosis or substance use (including alcohol-use disorders, or harmful use of or 
dependence on tobacco, cannabis, opioids, stimulants and non-prescriptions drugs). The 
population of interest was the general adult population aged 18 years or older. Exceptions 
were made for studies that included participants less than 18 years of age, and these were 
included if the majority of the sample (>70%) were 18+ years or the reported mean age was 
greater than 18+ years. Studies were included if they had a sample size greater than or equal 
to 450. This criterion has been used previously and ensures adequate statistical power to 
provide precise, reliable and stable prevalence estimates of the general population (2,12,13). 
Annex 3 provides further information about our inclusion and exclusion criteria.  
Literature search 
Previous reviews published until the end of 2013, which included data on the EMR, were used 
to identify primary cross-sectional and longitudinal studies that met the above-outlined 
eligibility criteria (7,10,14–16). Moreover, experts in the field were consulted to retrieve 
potential reviews that met the current review’s purpose (2,8). The literature search was 
conducted in five electronic databases, namely CINAHL Plus, PsycINFO, PubMed, Scopus 
and Web of Science. The search strategy was developed in PubMed, and Table 1 presents 
the specific keywords used. Annex 4 provides the exact search queries.  These searches were 
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amended in other databases to obtain optimal searching; for example, (.ti) and (.ti.ab) 
textwords were used in PsycINFO, instead of [Title] and [Title/Abstract] in PubMed. 
 
<< Put Table 1 around here >> 
 
Two searches were run on each database. The first search aimed to identify systematic 
reviews and meta-analyses published until the end of 2013. The second search focused on 
identifying new primary research such as cross-sectional and longitudinal studies conducted 
within the EMR countries from 2014 onwards to obtain recent prevalence estimates of mental 
disorders in the region that were not published in any of the previous systematic reviews 
(7,10,14–16). The literature search was conducted in July 2020 and restricted to English. We 
also repeated the search up to 2013 and did not find any non-included paper meeting inclusion 
criteria.  
 
Study Selection  
Title and abstracts were screened by one author (AZ), and a second reviewer (MH) screened 
40% (n= 4,921) of the articles. This was done in parallel to allow quality checks to be 
performed by analysing inter-rater reliabilities. Any discrepancies were resolved by a third 
team member (SN). The full texts were reviewed by at least two authors (AZ, AW, SN or MH) 
working independently from each other. Studies with overlapping samples (both time periods 
and regions) were considered as duplicates, with only the one which had complete data 
introduced to our meta-analyses.  
 
Data extraction 
Data were extracted by four authors (AZ, AW, SN, MH) using a manually constructed data 
extraction form (information on the type of data extracted is included in Annex 5). Data from 
each study were extracted by at least two reviewers working independently from each other. 




The Comprehensive Meta-Analysis software (17) was used to calculate the pooled prevalence 
rates for mental and substance use disorders using random-effects by employing the 
DerSimonian and Laird variance estimator and logit transformation. A random-effects model 
was chosen due to the anticipated heterogeneity in the data. The extent of heterogeneity was 
assessed using several statistics, including the I2 considered significant at > 40% and 
substantial at > 75%, Cochran’s Q-statistic considered significant at p < 0.05. Sensitivity 
analyses were conducted by running pooled analyses, with sequential removal of each study 
to assess its contribution to pooled prevalence rates and any significant changes therein. In 
addition, we assessed the contribution of outlier studies to quantify their contribution to pooled 
prevalence rates. Begg’s funnel plot (18) and Egger’s regression test (19) were used to 
evaluate publication bias, with significance set at p<0.10. Publication bias was adjusted for 
using Duval & Tweedie’s Trim and Fill method (20). Subgroup analyses were conducted for 
subgroups reported in more than four studies (8). This was to ensure appropriate statistical 
power to detect any differences. Furthermore, meta-regression analyses were conducted on 
the age of participants and country gross domestic product (GDP).  Both of these are 
significant predictors of some of the mental disorders and substance use; for instance, mental 
wellbeing is consistently shown to be affected by a country’s prosperity and poverty rates. 
Quality assessment  
The quality of studies was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal 
Checklist (21) for prevalence studies by at least two reviewers (AZ, SN or MH) working 
independently from each other, without blinding to the journal or authorship. The checklist 
consists of 8 items that assess the chance of bias in a study’s design, conduct and data 
analysis. Further details about the item responses and the process of calculating the quality 




The initial literature search yielded 808 systematic reviews (search #1) and 23,010 
observational studies (search #2). Two additional systematic reviews were identified by 
experts (2,8). A total of 473 non-duplicate systematic reviews (search #1) and 12,101 non-
duplicate observational studies (search #2) were obtained from the search strategies. Full 
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texts of 161 studies were assessed, and 54 prevalence studies were included in the meta-
analysis (22–75). The PRISMA flowchart is presented in Figure 1.  
 
<<Put Figure 1 around here>> 
 
Studies were published from 2001 to 2020, with most papers published after 2014 (n=39). All 
studies had a cross-sectional design, and all but one study was conducted in the community 
(one study was conducted online). Sixteen studies were conducted in Iran, five in Pakistan, 
five in Egypt, five in Lebanon, three in Sudan, three in Saudi Arabia, three in Morocco, three 
in Iraq, two in Afghanistan, two in Jordan, two in Qatar, one in Bahrain, one in Palestine and 
one in the United Arab Emirates (UAE), while two studies reported prevalence estimates 
across multiple countries – Pakistan, Tunisia and UAE. No studies from Djibouti, Kuwait, 
Libya, Oman, Somalia, Syria, and Yemen were identified. The majority of studies used various 
screening tools to measure the prevalence of mental disorders, and 28 studies utilized 
diagnostic interviews.  Further study characteristics are summarized in Appendix 6.  
The sample size ranged from 450 (56) to 130,570 participants (64). The mean age range of 
participants was 21.8 years to 73 years. Forty-seven studies focused on mental disorders in 
the general population, while seven were on trauma-exposed populations (n=2 on earthquake 
survivors, n=5 on refugees). The study sample sizes and main participant characteristics are 
further summarized in Appendix 7.  
A total of 36 (67%; 41 study cohorts) reported on the prevalence of depression (n=179,637), 
9 (17%; 12 study cohorts) on bipolar disorder (n=43,027), 19 (35%; 27 study cohorts) on GAD 
(n=179,944), 14 (26%; 15 study cohorts) on PTSD (n=58,567), 11 (20%) on OCD (n=58,058), 
11 (20%; 25 study cohorts) on phobic disorders (n=131,579), 10 (19%) on panic disorders 
(n=54,897), 21 (39%; 57 study cohorts) on substance use (n= 902,171) and 8 (15%; 18 study 
cohorts) on psychosis (n=182,547). Table 2 presents the pooled prevalence estimates 
(current, period or lifetime) for all mental disorders.  Estimates per type of prevalence for each 
disorder are provided in Table 3.  
 
<<Put Table 2 around here>> 





The prevalence for current, lifetime and period prevalence were 20.5% (95% CI: 14.9-
27.4%), 4.2% (95% CI: 1.8-9.6%), and 4.3% (95% CI: 1.2-13.5%) respectively (Table 3). 
The random-effects pooled prevalence of depressive disorders was estimated at 14.8% 
(95% CI: 10.7-20.1%) (Table 2). Substantial heterogeneity was present (I2= 99.81%, τ2 = 
1.44). The meta-analysis is presented in Appendix 8 (Forest plot Appendix 8.1). The 
sensitivity analyses did not reveal any significant changes in the prevalence of depressive 
disorders and the Egger’s test revealed no evidence of publication bias (p = 0.84). The 
funnel plot is given in Appendix 8.2. The results from subgroup analyses and meta-
regression are presented in Appendix 8.3 and 8.4, respectively. Subgroup analyses revealed 
major differences between the prevalence reported in studies using diagnostic interviews 
compared to those using screening tools (p<0.01), with studies using screening tools 
reporting four times the prevalence of depression (32.0%, 95% CI: 21.0-45.0%) than studies 
which employed diagnostic interviews (8.0%, 95% CI: 5.0-12.0%). Of the EMR countries, 
Afghanistan (33.0%, 95% CI: 7.0-75.0%), Egypt (22.0%, 95% CI: 8.0-47.0%), Jordan 
(37.0%, 95% CI: 9.0-78.0%), Lebanon (17.0%, 95% CI: 4.0-47.0%), Morocco (27.0%, 95% 
CI: 3.0-82.0%), Qatar (50.0%, 95% CI: 7.0-93.0%) and Sudan (40.0%, 95% CI: 10.0-80.0%) 
reported the highest prevalence, but difference in prevalence between the countries did not 
attain significance (p = 0.46). Additionally, higher prevalence of depression was reported 
among populations which were exposed to adversity, (33.0%, 95% CI: 11.0-66.0%), living 
under an authoritarian regime (16.0%, 95% CI: 11.0-23.0%), and living in low-income 
countries (28.0%, 95% CI: 11.0-54.0%). However, there was no evidence of a significant 
difference in prevalence estimates within these respective subgroups (p=0.11, 0.74, 0.44 
respectively). The meta-regression revealed no evidence of an association of depressive 
disorders with mean age (p=0.34) or with country GDP (p=0.10).  
 
Bipolar disorders  
The prevalence for current, lifetime and period prevalence were 1.9% (95% CI: 0.1-3.0%), 
0.2% (95% CI: 0.1-0.4%), and 0.6% (95% CI: 0.2-2.2%) respectively (Table 3). The random-
effects pooled prevalence of bipolar disorders was estimated at 0.7% (95% CI: 0.3-1.6%) 
(Table 2). Substantial heterogeneity was evident in the reporting of this outcome (I2=97.82%). 
Results for bipolar disorders are presented in Appendix 9 (Forest plot in Appendix 9.1). The 
sensitivity analyses did not reveal any significant changes in the prevalence of bipolar 
disorders. However, the Egger’s test showed evidence of publication bias (p=0.08) (funnel plot 
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in Appendix 9.2). Results from subgroup analyses and meta-regression are presented in 
Appendix 9.3 and 9.4, respectively. Subgroup analyses did not reveal any significant 
differences between EMR countries (p=0.89), regime types (p=0.58) or country’s income 
group (p=0.80). Additionally, the meta-regression showed no evidence of an association of 
bipolar disorder with mean age (p=0.14) or with country GDP (p=0.38). 
 
Generalised anxiety disorder  
The prevalence for current, lifetime and period prevalence were 10.3% (95% CI: 6.1-17.0%), 
4.5% (95% CI: 2.4-8.3%), and 6.0% (95% CI: 2.5-13.7%) respectively (Table 3). The random-
effects pooled prevalence of GAD was estimated at 6.9% (95% CI: 4.5-10.4%) (Table 2). 
Substantial heterogeneity was present (I2= 99.86%, τ2 = 1.37). Results for GAD are included 
in Appendix 10 (Forest plot presented in Appendix 10.1). The sensitivity analysis did not reveal 
any significant changes in the prevalence of GAD. However, the Egger’s test revealed 
evidence of publication bias (p<0.01) (funnel plot presented in Appendix 10.2). After adjusting 
for publication bias, the GAD’s pooled prevalence was estimated as 10.4% (95% CI: 7.1%-
14.7%). The results from subgroup analyses and meta-regression are presented in Appendix 
10.3 and 10.4, respectively. Subgroup analyses revealed that Afghanistan (25.0%, 95% CI: 
6.0-62.0%), Saudi Arabia (19.0%, 95% CI: 2.0-69.0%), Palestine (14.0%, 95% CI: 2.0-60.0%) 
and Iran (11.0%, 95% CI: 5.0-22.0%) had the highest prevalence of GAD. However, there was 
no evidence of a significant difference in prevalence between countries (p=0.18). Additionally, 
there was no evidence of differences between regime types (p=0.69). Low-income countries 
reported the highest GAD prevalence, but there was no evidence of a statistically significant 
difference between the countries based on their income levels (p=0.11). There was some 
evidence of a difference between screening methods (p=0.07), with studies using screening 
tools reporting double the prevalence (13.0%, 95% CI: 6.0%-26.0%) than diagnostic 
interviews (6.0%, 95% CI: 4.0%-9.0%). Studies including trauma-exposed populations 
reported double the prevalence of GAD (14.0%, 95% CI: 2.0-61.0%) than the general 
population (7.0%, 95% CI: 4.0-10.0%), but there was no evidence of a significant difference 
between the two population groups (p=0.52). Additionally, the meta-regression revealed no 
evidence of an association of GAD with mean age (p=0.13) or with country GDP (p=0.98).  
 
Post-traumatic stress disorder  
The prevalence for current and lifetime prevalence were 9.5% (95% CI: 4.2-20.1%) 8.3%) and 
3.3% (95% CI: 0.8-12.9%) respectively (Table 3). The random-effects pooled prevalence of 
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PTSD was estimated at 7.2% (95% CI: 2.9-16.6%) (Table 2). Substantial heterogeneity was 
present (I2= 99.73%, τ2 = 3.43). Results for PTSD are presented in Appendix 11 (forest plot 
included in Appendix 11.1). Sensitivity analysis did not reveal any significant changes in the 
prevalence of PTSD, and the Egger’s test revealed no evidence of publication bias (p=0.16) 
(funnel plot presented in Appendix 11.2). Results from subgroup analyses and meta-
regression are presented in Appendix 11.3 and 11.4 respectively. Subgroup analyses showed 
that Afghanistan (35.0%, 95% CI: 4.0-87.0%), Palestine (18.0%, 95% CI: 1.0-88.0%) and 
Sudan (36.0%, 95% CI: 2.0-95.0%) had the highest prevalence of PTSD. However, there was 
no evidence of a difference in prevalence between EMR countries (p=0.15). Studies that used 
screening tools reported over double the prevalence of PTSD (17.0%, 95% CI: 3.0-61.0%) 
compared to studies that employed diagnostic interviews (6.0%, 95% CI: 2.0-15.0%), but there 
was no evidence of a significant difference between the two (p=0.33). Generally, there was 
evidence of higher prevalence of PTSD in low-income countries (p=0.03) and some evidence 
that trauma-exposed populations had over six times the prevalence of PTSD (33.0%, 95% CI: 
6.0-80.0%) than the general population (5.0%, 95% CI: 2.0-13.0%) (p=0.05). The meta-
regression revealed no evidence of an association of PTSD with mean age (p=0.88). However, 
there was evidence of a negative association of PTSD with country GDP (p=0.04).  
 
Obsessive compulsive disorder  
The prevalence for current, lifetime and period prevalence were 2.7% (95% CI: 1.1-6.6%), 
2.2% (95% CI: 0.8-6.3%), and 1.4% (95% CI: 0.2-10.0%) respectively (Table 3). The random-
effects pooled prevalence of OCD was estimated at 2.8% (95% CI: 1.6-4.9%) (Table 2). 
Substantial heterogeneity was evident in the reporting of this outcome (I2= 99.01%, τ2 = 0.85). 
Results for OCD are presented in Appendix 12 (forest plot included in Appendix 12.1). 
Sensitivity analysis did not reveal any significant changes in the prevalence of OCD, and the 
Egger’s test revealed no evidence of publication bias (p=0.87) (funnel plot in Appendix 12.2). 
Results from the subgroup analyses and meta-regression are presented in Appendix 12.3 and 
12.4, respectively. Subgroup analyses revealed evidence of a difference between EMR 
countries (p=0.01) with Morocco (6.0%, 95% CI: 2.0-21.0%), Iran (6.0%, 95% CI: 2.0-14.0%) 
and Iraq (5.0%, 95% CI: 1.0-25.0%) reporting higher prevalence of OCD. There was also 
evidence of prevalence differing across countries based on their income groups (p=0.01), with 
high-income countries reporting the lowest prevalence of OCD (0.1%, 95% CI: 0.0%-1.0%). 
The meta-regression revealed no evidence of an association of OCD with mean age (p=0.66) 
or with country GDP (p=0.74).  
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Phobic disorders  
The prevalence for current, lifetime and period prevalence were 2.6% (95% CI: 1.3-5.2%), 
1.2% (95% CI: 0.6-2.5%), and 1.7% (95% CI: 0.3-10.4%) respectively (Table 3). The random-
effects pooled prevalence of phobic disorders was estimated at 1.8% (95% CI: 1.1-2.8%) 
(Table 2). Substantial heterogeneity was evident in the reporting of this outcome (I2= 99.23%, 
τ2 = 1.35). Results for phobic disorders are included in Appendix 13 (forest plot presented in 
Appendix 13.1). Sensitivity analysis did not reveal any significant changes in the prevalence 
of phobic disorders, and the Egger’s test revealed no evidence of publication bias (p=0.13) 
(funnel plot included in Appendix 13.2). Results from the subgroup analyses and meta-
regression are presented in Appendix 13.3 and 13.4 respectively. Subgroup analyses 
revealed strong evidence for differences in the prevalence of phobic disorders across EMR 
countries (p<0.01), with the highest prevalence in Sudan (14.0%, 95% CI: 4.0-39.0%) and 
Morocco (8.0%, 95% CI: 4.0-13.0%). There was also evidence of differences across country 
income groups (p<0.01), with the highest prevalence reported in low-income countries (14.0%, 
95% CI: 26.0-58.0%). Additionally, there was evidence of a difference across population type 
(p=0.04) and regime type (p=0.01), with populations exposed to adversity having seven times 
the prevalence of phobic disorders (14.0%, 95% CI: 2.0-60.0%) than the general population 
(2.0%, 95% CI: 1.0-3.0%), and populations living under hybrid regimes having four times the 
prevalence (4.0%, 95% CI: 2.0-8.0%) than those under authoritarian regimes (1.0%, 95% CI: 
1.0-2.0%). The meta-regression revealed no evidence of an association of phobic disorders 
with mean age (p=0.15), but there was evidence of a negative association with country GDP 
(p=0.04). 
 
Panic disorders  
The prevalence for current, lifetime and period prevalence were 0.9% (95% CI: 0.0-0.3%), 
1.3% (95% CI: 0.1-0.3%), and 0.9% (95% CI: 0.0-0.7%) respectively (Table 3). The random-
effects pooled prevalence of panic disorders was estimated at 1.1% (95% CI: 0.6-2.2%) (Table 
2). Substantial heterogeneity was evident in the reporting of this outcome (I2= 98.69%, τ2 = 
1.09). Results for panic disorders are presented in Appendix 14 (forest plot included in 
Appendix 14.1). Sensitivity analysis did not reveal any significant changes in the prevalence 
of panic disorders, and the Egger’s test showed no evidence of publication bias (p=0.31) 
(funnel plot in Appendix 14.2). Results from the subgroup analyses and meta-regression are 
presented in Appendix 14.3 and 14.4, respectively. Subgroup analyses revealed evidence for 
differences in the prevalence of panic disorders across EMR countries (p<0.01), with Morocco 
reporting the highest prevalence (4.0%, 95% CI: 2.0-10.0%). There was also evidence of a 
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difference between regime type (p=0.02), with populations living under hybrid regimes 
reporting a higher prevalence of panic disorders (3.0%, 95% CI: 1.0-5.0%) than those under 
authoritarian regimes (1.0%, 95% CI: 1.0-2.0%). The meta-regression revealed no evidence 
of an association of panic disorders with country GDP (p=0.16) 
 
Substance use  
The prevalence for current, lifetime and period prevalence were 8.4% (95% CI: 4.9-14.1%), 
3.3% (95% CI: 2.4-4.7%), and 1.3% (95% CI: 0.8-2.1%) respectively (Table 3). The random-
effects pooled prevalence of substance use was estimated at 3.0% (95% CI: 2.3-3.9%) (Table 
2). Substantial heterogeneity was evident in the reporting of this outcome (I2= 99.94%, τ2= 
1.02). Results for substance use are presented in Appendix 15 (forest plot included in 
Appendix 15.1). Sensitivity analysis did not reveal any significant changes in the prevalence 
of substance use. Among eight of these studies, pooled prevalence for tobacco use alone was 
estimated at 23.3% (95% CI: 19.2% to 28.1%, I2= 99.85%, 280,826) (Appendix 15.5).  
The Egger’s test revealed strong evidence of publication bias (p<0.01) (funnel plot is 
presented in Appendix 15.2). After adjusting for publication bias, the pooled prevalence of 
substance use was estimated at 4.02% (95% CI: 3.1-5.2%). Results from the subgroup 
analyses and meta-regression are presented in Appendix 15.3 and 15.4, respectively. 
Subgroup analyses revealed strong evidence for differences in the prevalence of substance 
use across EMR countries (p<0.01), with Pakistan (32.0%, 95% CI: 6.0-78.0%), Qatar (29.0%, 
95% CI: 5.0-75.0%), Morocco (15.0%, 95% CI: 8.0-26.0%) and Saudi Arabia (14.0%, 95% CI:  
5.0-34.0%) reporting the highest prevalence. There was also strong evidence of differences 
across country income subgroups (p<0.01), with high-income countries reporting the highest 
prevalence (10.0%, 95% CI: 4.0-21.0%). The prevalence also differed across regime types 
and screening method (p<0.01 for both), with hybrid regimes and studies using screening tools 
as opposed to diagnostic interviews reporting higher prevalence of substance use 
(13.0%,95% CI: 7.0-22.0% and 8.0%, 95% CI: 6.0-11.0% respectively). The meta-regression 
also revealed evidence of a positive association of substance use with mean age (p<0.01). 




The prevalence for current, lifetime and period prevalence were 1.3% (95% CI: 0.4-4.1%), 
0.3% (95% CI: 0.1-0.7%), and 0.4% (95% CI: 0.1-1.3%) respectively (Table 3). The random-
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effects pooled prevalence of psychosis was estimated at 0.5% (95% CI: 0.3-0.9%) (Table 2). 
Substantial heterogeneity was evident in the reporting of this outcome (I2=97.93%). Results 
for psychosis are included in Appendix 16 (forest plot included in Appendix 16.1). Sensitivity 
analysis did not reveal any significant changes in the prevalence of psychosis, and the Egger’s 
test revealed no evidence of publication bias (p=0.42) (funnel plot is included in Appendix 
16.2). Results from the subgroup analyses and meta-regression are presented in Appendix 
16.3 and 16.4, respectively. Subgroup analyses revealed a higher prevalence of psychosis in 
low-income countries (5.6%, 95% CI: 0.8-30.8%). However, there was no evidence of a 
difference between the prevalence of psychosis across country’s income group or EMR 
countries and screening method (p > 0.05). The meta-regression revealed no evidence of an 
association of psychosis with mean age (p=0.38) or with country GDP (p=0.32). 
 
Quality assessment  
The quality assessment of all included studies is presented in Appendix 17. Most studies were 
rated as medium-quality (n=28), with 22 rated as high-quality and only four rated as low-
quality. Across the items, all studies had an adequate sample size (n=54). Additionally, the 
majority of studies had an appropriate sampling frame (n=50) and sampling method (n=49), 
appropriate statistics (n=48) and appropriate details of the sample and setting (n=42). Fewer 
studies conducted data analysis with sufficient coverage (n=29), employed valid (n=34) and 




The current review included 54 studies that reported prevalence estimates for mental and 
substance use disorders across 15 countries in the WHO EMR. Depressive disorders showed 
the highest pooled prevalence of current, period and lifetime prevalence (14.8%, 95% CI: 10.7-
20.1%), followed by GAD (10.4%, 95% CI: 7.1-14.7%), PTSD (7.2%, 95% CI: 2.9-16.6%), 
substance use (4.0%, 95% CI: 3.1-5.2%), OCD (2.8%, 95% CI: 1.6-4.9%), phobic disorders 
(1.8%, 95% CI: 1.1-2.8%), panic disorders (1.1%, 95% CI: 0.6-2.2%), bipolar disorders (0.7%, 
95% CI: 0.3–1.6%) and psychosis (0.5%, 95% CI: 0.3-0.9%). Period and lifetime prevalence 
showed little difference across mental disorders. More pronounced differences in prevalence 
were seen for depression and GAD, specifically between current and lifetime prevalence 
(depression: current prevalence 20.5% (95% CI: 14.9-27.4%), vs. lifetime prevalence: 4.2% 
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(95%CI: 1.8-9.6%); GAD: current prevalence 10.3% (95% CI: 6.1-17.0), vs. lifetime 
prevalence: 4.5% (95% CI:2.4-8.3%). 
Our findings correspond to the current evidence base. For example, depression was the most 
prevalent disorder within our review, a finding that is consistent with previous systematic 
reviews in the EMR (76) and the regional prevalence recently reported by WHO (77). The 
prevalence of depression in the EMR is higher than the global prevalence (4.7%, 95% CI: 4.4–
5.0%) (15), which can be explained by the ongoing conflict and unrest in the majority of the 
EMR countries (78,79). Similarly, our pooled prevalence estimate for bipolar disorder (0.7%, 
95% CI: 0.3-1.6%) is consistent with the global prevalence estimate of 0.74% (14). Other 
reviews have found that the prevalence of bipolar disorders is between 1% to 2% (13,80). Our 
period prevalence for GAD is 6.0% (95% CI: 2.5-13.7%) which corresponds with the period 
prevalence for anxiety disorders (including GAD) reported by Steel and colleagues (6.7%, 
95% CI: 6.1–7.9%) (2). Similarly, the lifetime prevalence for PTSD which we have found (3.3%, 
95% CI: 0.8-12.9%) corresponds to the WMHS estimate of 3.2% (95% CI: 3.0–3.4%) (81). For 
OCD, the period prevalence (1.4%, 95% CI: 0.2-10.0%) and lifetime prevalence (2.2%, 95% 
CI: 0.8-6.3%) obtained in this review are greater than previous global 1-year 0.54% (95% CI: 
0.28-0.86%) and lifetime estimate (1.3%; 95% CI: 0.86-1.8%) as reported by Somers and 
colleagues (12). As for phobic disorders, the period prevalence (1.7%, 95% CI: 0.3-10.4%) 
and lifetime prevalence (1.2%, 95% CI: 0.6-2.5%) obtained in our review is also less than 
Somers et al’s 1-year (3.0%, 95% CI: 0.98-5.8%) and lifetime estimates (5.3%, 95% CI: 3.4-
7.9%) (12).  However, our estimates for panic disorders, specifically the period prevalence 
estimate (0.9%, 95% CI: 0.0-0.7%) corresponds to findings by Somers et al (0.99%,95% CI:  
0.55-1.5%). Furthermore, our lifetime estimate for panic disorders (1.3%, 95% CI: 0.1-0.3%) 
is similar to Somer et al’s lifetime estimates (1.2%, 95% CI: 0.7-1.9%) (12). Although there 
seems to be consistency in prevalence estimates for panic disorders across regions, overall, 
there is a paucity of evidence on OCD, phobic and panic disorders and therefore, any 
variations as well as similarities in the results require further investigation into the source of 
these trends. The pooled prevalence of substance use after adjusting for publication bias 
(4.0%, 95% CI: 3.1- 5.2%) is similar to global period prevalence estimates (3.8%, 95% CI: 
3.3–4.2%) (2). Additionally, the global lifetime prevalence estimate obtained by other authors 
(10.7%, 95% CI: 9.2–12.5%) (2) is higher than the lifetime prevalence estimate obtained in 
the current study (3.3%, 95% CI: 2.4-4.7%). Research on substance use faces challenges 
within the region due to stigma and their illegal status and therefore, it may be difficult to 
assess their true prevalence. Psychosis shows the lowest pooled prevalence among all mental 
disorders (0.5%, 95% CI: 0.3-0.9%), confirming global trends. Psychosis has been reported 
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higher in conflict-affected settings with an established association between psychotic 
symptoms and PTSD (82). 
 
Subgroup analyses and meta-regression  
Subgroup analyses on EMR countries, population type, regime type, screening method 
(diagnostic or non-diagnostic), and country’s income group revealed possible reasons for the 
heterogeneity observed. The prevalence of OCD, panic disorders, phobic disorders and 
substance use varied significantly across EMR countries. Additionally, populations exposed 
to adversity had a higher prevalence (between two to seven times) than the general 
population. However, this difference was only significant for phobic disorders and marginally 
significant for PTSD. Higher rates of depressive disorders, GAD, PTSD, phobic disorders and 
psychosis were observed in low-income countries, with evidence of a difference in the 
prevalence of PTSD and phobic disorders across income groups.  
Additionally, individuals in hybrid regimes were found to be significantly more likely to show 
phobic and panic disorders, as well as substance use. Substance use was also found to be 
significantly higher in high-income countries. Finally, studies that used screening tools 
reported a consistently higher prevalence of mental disorders than studies that used 
diagnostic interviews. Significantly higher rates were reported for depressive disorders and 
substance use and marginally significantly higher rates for GAD.  
In addition to subgroup analyses, meta-regression analyses were also performed to assess 
the variation in prevalence estimates of mental disorders and substance use based on the 
age of participants and country GDP. Meta-regression analyses in the current review revealed 
that substance use was positively associated with mean age. Furthermore, country GDP was 
found to be negatively associated with both PTSD and phobic disorders. A discussion on 
further trends across other country-level factors, age of participants and population type is 






Strengths and limitations   
 
This study synthesizes current evidence on the prevalence of mental and substance use 
disorders within the EMR, with a search strategy adapted from previous reviews (8,83). 
However, title and abstract screening was predominately done by one author, with another 
author double screening 40% of the articles only. This selection process was chosen due to 
time constraints and may have increased the chances of missing relevant studies. On the 
other hand, all full texts were reviewed by at least two authors working independently from 
each other. We did not search for grey literature and conducted the literature search in English 
only. Furthermore, we did not search for cross-sectional studies before 2014 and relied on 
data from systematic reviews published until then. Therefore, it may be possible that some 
individual studies were missed.  
At the data extraction stage, lifetime prevalence estimates were preferred over current or 
period prevalence rates (rational provided in Annex 5). However, lifetime prevalence estimates 
may be more susceptible to recall bias due to a more extended period of recall (2). 
Furthermore, we combined current, period and lifetime prevalence estimates (Table 2) to be 
able to include a larger number of studies per disorder type but separate analyses were also 
conducted taking account of possible differences in prevalence (see Table 3). However, some 
of these are based on a low number of studies which may hamper generalisability of findings. 
Prevalence estimates for some of the mental disorders were very low, and even larger sample 
sizes (>500) had higher margin of errors and imprecise estimates, rendering some of our 
pooled estimates (table 2) asymmetric. Additionally, substance use included tobacco use, 
which generally has a high population prevalence and may have affected the overall 
prevalence estimate (2) (forest plot for tobacco use included in the supplementary material). 
Separate analyses by type of prevalence was also being conducted. Period and lifetime 
prevalence showed little difference across mental disorders. More pronounced differences in 
prevalence were seen for depression and GAD and these differences between current and 
lifetime prevalence for depression and GAD may be due to the use of different screening 
instruments and thresholds being applied.  
There are a few methodological factors that need to be considered as well. First, around 28% 
of the studies had an under-representation of adults aged 50+ years which may affect the 
generalisability of the findings to older age-groups. Second, around 13% of studies were rated 
to have an inadequate response rate (less than 85%), and 37% of the studies did not specify 
the response rate. This may have led to more conservative estimates as non-respondents 
may have potentially higher rates of mental disorders (84,85). Third, substantial heterogeneity 
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was identified in all random effect models, with I2 exceeding 95% in each of them. 
Heterogeneity can have an adverse effect on the inter-survey comparability and the reliability 
and interpretability of the pooled prevalence estimates. However, sensitivity analyses yielded 
no significant changes in any of the estimates, thereby confirming the stability of the 
prevalence estimates to a large extent. Finally, the majority of studies employed screening 
tools only which may have overestimated prevalence of mental disorders.  
 
Conclusion  
The prevalence of mental and substance use disorders in the EMR is high. Despite substantial 
inter-survey heterogeneity, our estimates align with previous data on mental and substance 
use disorders at the global and regional level. Our systematic review and meta-analysis 
provide important new evidence to better understand the burden of mental and substance use 
disorders in the EMR, which may facilitate future mental health research and policymaking in 
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Figure 1. Flowchart  
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Table 3. Mental disorders in the EMR by type of prevalence  
 
Prevalence type No. of cohorts Prevalence (%)  95% CI I2 (%) 
Depressive disorder     
Current 32 20.5 14.9% - 27.4% 99.78 
Lifetime 6 4.2 1.8% - 9.6% 99.78 
Period 3 4.3 1.2% - 13.5% 93.99 
Bipolar disorder     
Current 6 1.9 0.1% - 3.0% 85.98 
Lifetime 5 0.2 0.1% - 0.4% 19.63 
Period 1 0.6 0.2% - 2.2% 0 
GAD     
Current 12 10.3 6.1% - 17.0% 99.89 
Lifetime 10 4.5 2.4% - 8.3% 99.42 
Period 5 6.0 2.5% - 13.7% 98.04 
PTSD     
Current 11 9.5 4.2% - 20.1% 99.60 
Lifetime 4 3.3 0.8% - 12.9% 99.50 
OCD     
Current 5 2.7 1.1% - 6.6% 99.13 
Lifetime 4 2.2 0.8% - 6.3% 99.20 
Period 1 1.4 0.2% - 10.0% 0 
Phobic disorders     
Current 11 2.6 1.3% - 5.2% 99.33 
Lifetime 12 1.2 0.6% - 2.5% 99.17 
Period 2 1.7 0.3% - 10.4% 94.37 
Panic disorders     
Current 3 0.9 0.0% - 0.3% 90.95 
 27 
Lifetime 6 1.3 0.1% - 0.3% 98.97 
Period 1 0.9 0.0% - 0.7% 0 
Substance use     
Current 10 8.4 4.9% - 14.1% 99.94 
Lifetime 30 3.3 2.4% - 4.7% 99.95 
Period 17 1.3 0.8% - 2.1% 99.64 
Psychosis     
Current 5 1.3 0.4% - 4.1% 97.51 
Lifetime 8 0.3 0.1% - 0.7% 98.87 
Period 5 0.4 0.1% - 1.3% 24.69 
 
 
